Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7097725 | 0.89 | — | — | |
| SCHEMBL1746 | 0.89 | — | — | |
| SCHEMBL5544690 | 0.89 | MEN1 (0.42) | MEN1KMT2A | |
| Fluoride SCHEMBL73855 | 0.86 | MEN1 (0.40) | MEN1KMT2A | |
| Iodide SCHEMBL115029 | 0.86 | MEN1 (0.40) | MEN1KMT2A | |
| SCHEMBL319537 | 0.86 | MEN1 (0.40) | MEN1KMT2A | |
| Ammonia Solution, Strong SCHEMBL1997314 | 0.86 | MEN1 (0.40) | MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL22577541 | 0.86 | MEN1 (0.40) | MEN1KMT2A | |
| SCHEMBL2232066 | 0.86 | MEN1 (0.40) | MEN1KMT2A | |
| Fluoride SCHEMBL1025917 | 0.86 | MEN1 (0.40) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 208 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024075131-A1 | CO-CRYSTAL OF UPADACITINIB AND DIACETYL-D-TARTARIC ACID AND PROCESS FOR THE PREPARATION THEREOF | NATCO PHARMA LIMITED (IN) | 2024-04-11 | — | — | WO | claimed |
| CN-110615859-B | Preparation method of sodium gluconate | 鲁南制药集团股份有限公司 | 2023-10-20 | — | — | CN | claimed |
| CN-111574463-B | Rivastigmine intermediate compound IV | 鲁南制药集团股份有限公司 | 2023-07-14 | — | — | CN | claimed |
| WO-2023119100-A1 | STABLE PHARMACEUTICAL COMPOSITIONS | MANKIND PHARMA LTD. (IN) | 2023-06-29 | — | — | WO | claimed |
| WO-2023105497-A1 | SYNTHESIS OF GLP-1 ANALOGUES | ANTHEM BIOSCIENCES PVT. LTD. (IN) | 2023-06-15 | — | — | WO | claimed |
| CN-112028851-B | Parecoxib sodium intermediate compound | 鲁南制药集团股份有限公司 | 2023-05-02 | — | — | CN | claimed |
| WO-2023286078-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF AN INTERMEDIATE OF BALOXAVIR MORBOXIL | NATCO PHARMA LIMITED (IN) | 2023-01-19 | — | — | WO | claimed |
| CN-113121394-B | Preparation method of phenoxyacetic acid derivative | 中国药科大学 | 2022-11-08 | — | — | CN | claimed |
| CN-110256342-B | Synthetic method of 2-cyano quinoline derivative | 河南省科学院化学研究所有限公司 | 2022-06-07 | — | — | CN | claimed |
| WO-2021260498-A1 | AN IMPROVED PURIFICATION PROCESS FOR THE PREPARATION OF ERTUGLIFLOZIN AND ERTUGLIFLOZIN L-PYROGLUTAMIC ACID CO-CRYSTAL | AUROBINDO PHARMA LIMITED (IN) | 2021-12-30 | — | — | WO | claimed |
| US-20110015189-A1 | METHODS OF MAKING EFAVIRENZ AND INTERMEDIATES THEREOF | APOTEX PHARMACHEM INC. (CA) | 2011-01-20 | — | — | US | claimed |
| US-20060293307-A1 | Oxazolidinone derivatives as antimicrobials | RANBAXY LABORATORIES LIMITED (IN) | 2006-12-28 | — | — | US | claimed |
| EP-1542696-A4 | OXAZOLIDINONE DERIVATIVES AS ANTIMICROBIALS | RANBAXY LAB LTD (IN) | 2006-08-02 | — | — | EP | claimed |
| EP-1620433-A1 | OXAZOLIDINONE DERIVATIVES AS ANTIMICROBIALS | RANBAXY LABORATORIES, LTD. (IN) | 2006-02-01 | — | — | EP | claimed |
| EP-1542696-A1 | OXAZOLIDINONE DERIVATIVES AS ANTIMICROBIALS | RANBAXY LABORATORIES, LTD. (IN) | 2005-06-22 | — | — | EP | claimed |
| WO-2004089944-A1 | OXAZOLIDINONE DERIVATIVES AS ANTIMICROBIALS | RANBAXY LABORATORIES LIMITED (US) | 2004-10-21 | — | — | WO | claimed |
| WO-2004014392-A1 | OXAZOLIDINONE DERIVATIVES AS ANTIMICROBIALS | RANBAXY LABORATORIES LIMITED (IN) | 2004-02-19 | — | — | WO | claimed |
| US-5817806-A | Process for the preparation of cyclohexyl-azetidinones | GLAXO WELLCOME SPA (IT) | 1998-10-06 | — | — | US | claimed |
| EP-0752984-A1 | PROCESS FOR THE PREPARATION OF CYCLOHEXYL-AZETIDINONES | GLAXO WELLCOME S.p.A. (IT) | 1997-01-15 | — | — | EP | claimed |
| WO-1995026333-A1 | PROCESS FOR THE PREPARATION OF CYCLOHEXYL-AZETIDINONES | GLAXO WELLCOME S.P.A. (IT) | 1995-10-05 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060293307-A1 | Oxazolidinone derivatives as antimicrobials | OXA1L, PDK4, SDHA | MEN1 4318/4885KMT2A 4636/4885 |
| US-20110015189-A1 | METHODS OF MAKING EFAVIRENZ AND INTERMEDIATES THEREOF | CYP2F1, CYP4F11, CYP4F3 | MEN1 4341/4885KMT2A 3154/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.